In step toward personalized medicine, FDA approves BiDil

Taking what it described as a step toward personalized medicine, the FDA has approved NitroMed's Bidil, a heart medication that was successful in trials involving African-Americans. The drug has aroused intense controversy as some critics contend that a drug designed exclusively for blacks could reignite racist arguments about the biological differences of whites and blacks. Medical experts, though, contend that the approval provides blacks with a significant new therapy. And the FDA maintains that they are ready to examine drugs that are effective in other groups regardless of race.

- read this article from The Washington Post

ALSO: The FDA has also approved UCB Pharma's Keppra for epilepsy. Release